MIRA Pharmaceuticals, Inc. Proceeds from Lines of Credit
MIRA Pharmaceuticals, Inc. (MIRA) reported Proceeds from Lines of Credit of $86.48 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow
us-gaap:ProceedsFromLinesOfCredit · last filed 2024-05-13
- MIRA Pharmaceuticals, Inc. proceeds from lines of credit for the quarter ending 2023-03-31 was $86.48K.
| Period end | Proceeds from Lines of Credit 3 month |
|---|---|
| 2023-03-31 | $86.48K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |